Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Childhood leukemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    36 result(s) found for: Childhood leukemia. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2014-003303-30 Sponsor Protocol Number: 2014-003303-30 Start Date*: 2015-05-22
    Sponsor Name:Dutch Childhood Oncology Group
    Full Title: TropicALL study; Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a randomized controlled trial
    Medical condition: Acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001236-21 Sponsor Protocol Number: 2008-003235-20 Start Date*: 2013-06-11
    Sponsor Name:Kjeld Schmiegelow
    Full Title: Plasma kinetics for tablet and liquid formulations of 6-mercaptopurine in childhood acute lympholastic leukemia
    Medical condition: Childhood acute lymphoblastic leukemia.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-002288-14 Sponsor Protocol Number: HM1006 Start Date*: 2009-02-10
    Sponsor Name:University of Birmingham
    Full Title: Phase I Dose Escalation Study of Clofarabine and Liposomal Daunorubicin in Childhood and Adolescent AML
    Medical condition: Paediatric patients (6 months to 18 years) diagnosed with AML who are refractory to front line therapy, early first relapse (less than 1 year from diagnosis) and second and subsequent relapse patie...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000880 Acute myeloid leukaemia LLT
    9.1 10066764 Acute myeloid leukaemia progression LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-000067-25 Sponsor Protocol Number: ALL11 Start Date*: 2012-10-19
    Sponsor Name:Princess Máxima Center for pediatric oncology
    Full Title: Protocol ALL-11: Treatment study protocol of the Dutch Childhood Oncology Group for children and adolescents (1-19 year) with newly diagnosed acute lymphoblastic leukemia
    Medical condition: Acute lymphoblastic leukemia in children
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-022946-25 Sponsor Protocol Number: AALL0622 Start Date*: 2011-12-19
    Sponsor Name:Children's Oncology Group
    Full Title: Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib: IND# 73969, NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL)
    Medical condition: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000844 Acute lymphoblastic leukaemia LLT
    14.1 10022891 - Investigations 10034877 Philadelphia chromosome positive LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-004090-26 Sponsor Protocol Number: 6MP/6TG-01 Start Date*: 2008-03-25
    Sponsor Name:Rigshospitalet
    Full Title: IMPROVING THIOPURINE/METHOTREXATE MAINTENANCE THERAPY OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA
    Medical condition: Acute Lymphoblastic Leucemia in children and adolescents
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-000557-88 Sponsor Protocol Number: Anti-CD19-ALL Start Date*: 2022-11-14
    Sponsor Name:University Hospital Tuebingen
    Full Title: A Prospective Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (MOR00208) in Pediatric Patients with Relapsed or Refractory Acute B Lineage L...
    Medical condition: B-lineage (CD19 positive) ALL (B, pro-B, pre-B or c-ALL) refractory to standard treatment or with relapsed disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10024338 Leukemia lymphoblastic acute LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005281-29 Sponsor Protocol Number: IVAC-ALL-1 Start Date*: 2016-06-07
    Sponsor Name:University Hospital Tuebingen
    Full Title: Prospective phase I/II study: Patient-individualized peptide vaccination based on whole exome sequencing with adjuvant GM-CSF in children with relapsed acute lymphoblastic leukemia
    Medical condition: Relapsed acute lymphatic leukemia
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10000842 Acute lymphatic leukaemia LLT
    18.1 100000004864 10054444 Leukemia relapse LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001561-27 Sponsor Protocol Number: 2000790 Start Date*: 2014-08-25
    Sponsor Name:VU university medical center
    Full Title: Vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia: comparing one-hour infusions with short-term infusions (the VINCA-study)
    Medical condition: Pediatric oncology, acute lymphoblastic leukemia, nephroblastoma, medulloblastoma, low-grade glioma, Hodgkin lymphoma, rhabdomyosarcoma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10001690 ALL LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003235-20 Sponsor Protocol Number: NOPHO-ALL-2008 Start Date*: 2008-10-10
    Sponsor Name:Rigshospitalet
    Full Title: NOPHO-ALL-2008 Treatment Protocol for Children (1.0 - 17.9 years of age) with Acute Lymphoblastic Leukemia
    Medical condition: Acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) SE (Completed) FI (Completed) LT (Prematurely Ended) IS (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001647-30 Sponsor Protocol Number: ESPHALL Start Date*: 2004-04-28
    Sponsor Name:A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA
    Full Title: An open-label study to evaluate the safety and efficacy of IMATINIB with chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL)
    Medical condition: Children and adolescents aged 1-17 years at diagnosis, with Ph+ALL
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005066-30 Sponsor Protocol Number: RG_14-088 Start Date*: 2018-03-20
    Sponsor Name:The University of Birmingham
    Full Title: MyeChild 01: International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with ...
    Medical condition: Newly diagnosed acute myeloid leukaemia (AML), high risk myelodysplastic syndrome(MDS) and isolated myeloid sarcoma (either de novo or secondary) are eligible for the trial.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IE (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-004599-19 Sponsor Protocol Number: INTERFANT-06 Start Date*: 2005-11-24
    Sponsor Name:A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA
    Full Title: INTERNATIONAL COLLABORATIVE TREATMENT PROTOCOL FOR INFANTS UNDER ONE YEAR WITH ACUTE LYMPHOBLASTIC OR BIPHENOTYPIC LEUKEMIA
    Medical condition: acute lymphoblastic leukemia (ALL) or biphenotypic leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) BE (Completed) FR (Ongoing) DE (Completed) GB (Completed) AT (Ongoing) PT (Completed) DK (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2007-007612-29 Sponsor Protocol Number: UCL/09/0050 Start Date*: 2013-02-26
    Sponsor Name:University College London
    Full Title: Immunotherapy with CD19ζ chimeric antigen receptor gene-modified EBV-specific CTLs after stem cell transplant in children with high-risk acute lymphoblastic leukaemia
    Medical condition: The medical condition under investigation is childhood precursor B acute lymphoblastic leukaemia (ALL).
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-014037-25 Sponsor Protocol Number: ITCC021 Start Date*: 2010-01-11
    Sponsor Name:Erasmus MC
    Full Title: Bortezomib (Velcade®): a feasibility and phase II study in childhood relapsed acute lymphoblastic leukemia
    Medical condition: acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    12.0 10063625 Acute lymphoblastic leukemia recurrent LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) IT (Completed) BE (Completed) DK (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004270-43 Sponsor Protocol Number: AIEOP-BFMALL2009 Start Date*: Information not available in EudraCT
    Sponsor Name:Universitätsklinikum Schleswig-Holstein, Campus Kiel
    Full Title: International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia
    Medical condition: acute lymphoblastic leukemia in children and adolescents 1 to <18 years of age
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) AT (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003409-33 Sponsor Protocol Number: AllopurinolALL3.1 Start Date*: 2016-12-09
    Sponsor Name:Västra Götaland Regionen
    Full Title: Optimizing 6-mercaptopurine therapy in pediatric acute lymphoblastic leukemia by using allopurinol. Clinical study in children 1-19 years on maintenance therapy for acute lymphoblastic leukemia.
    Medical condition: Acute lymphoblastic leukemia diagnosed at age 0-18 in children
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006239-44 Sponsor Protocol Number: NL37603.042.11 Start Date*: 2012-10-02
    Sponsor Name:Dutch Childhood Oncology Group
    Full Title: An international collaborative study to discontinue Imatinib/Glivec® in pediatric CML patients with sustained complete molecular response (STOPIMAPED)
    Medical condition: Chronic Myeloid Leukemia pediatric patients treated with Imatinib having achieved and maintained complete molecular remission for at least 2 years.
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004541-33 Sponsor Protocol Number: immvzmpr1 Start Date*: Information not available in EudraCT
    Sponsor Name:Västra Götalandsregionen
    Full Title: A clinical study to examine cellular and humoral immunity against measles and chickenpox in children and adolescents 0-18 years in childhood cancer.
    Medical condition: This study will be conducted as a longitudinal study. Former studies have shown that immunity is affected after treatment against childhood cancer. We want to investigate humoral and cell-mediated ...
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-004021-19 Sponsor Protocol Number: NOPHO ALL 2008 pilot Start Date*: 2008-03-25
    Sponsor Name:Rigshospitalet
    Full Title: NOPHO ALL-2008 PILOT STUDY ON CONSOLIDATION THERAPY FOR CHILDREN AND YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA
    Medical condition: Acute lymphoblastic leukemia in children 1.0-18 years of age
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066109 Precursor B-lymphoblastic leukemia acute LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) FI (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 17:40:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA